Beena O. Pappen
Publications by Year
Research Areas
Immunotherapy and Immune Responses, Cancer Research and Treatments, Virus-based gene therapy research, CAR-T cell therapy research, RNA Interference and Gene Delivery
Most-Cited Works
- → Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer(2006)359 cited
- → A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors(2009)266 cited
- → Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer(2011)193 cited
- → Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients(2009)146 cited
- → Induction of Immune Responses and Clinical Efficacy in a Phase II Trial of IDM-2101, a 10-Epitope Cytotoxic T-Lymphocyte Vaccine, in Metastatic Non–Small-Cell Lung Cancer(2008)98 cited
- → Three-year Follow up of GMCSF/bi-shRNAfurin DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma(2016)94 cited
- → Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer(2016)88 cited
- → Phase I Trial of Sequential Administration of Recombinant DNA and Adenovirus Expressing L523S Protein in Early Stage Non-Small-Cell Lung Cancer(2006)69 cited
- → Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine(2011)54 cited
- → Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma(2015)53 cited